Skip to main content
SpringerLink
Log in

NICE issues new guidance for hep B, CLL therapies

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. NICE.NICE guidance recommends tenofovir disoproxil for hepatitis B. Media Release: 22 Jul 2009. Available from: URL: http://www.nice.org.uk

  2. NICE.NICE issues final guidance on the use of rituximab for first line chronic lymphocytic leukaemia. Media Release: 22 Jul 2009. Available from: URL: http://www.nice.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

NICE issues new guidance for hep B, CLL therapies. Pharmacoecon. Outcomes News 584, 3 (2009). https://doi.org/10.2165/00151234-200905840-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905840-00006

Keywords

Search

Navigation